A cost minimisation analysis of NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients, pre- and post- cardioversion

M. O’Shea; A. Murphy; Ann Kirby; G. Allen; S. O’Shea; R. Curtin

A cost minimisation analysis of NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients, pre- and post- cardioversion

M. O’Shea
, A. Murphy
, Ann Kirby
, G. Allen
, S. O’Shea
, R. Curtin

Cork University Business School

University College Cork

Research output: Contribution to journal › Article › peer-review

Abstract

Atrial fibrillation can be managed with anticoagulation and restoration of normal sinus rhythm using direct current cardioversion (DCCV). To reduce the risk of thromboembolism, anticoagulation pre-and-post DCCV is recommended. This study investigates the cost effectiveness of using NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-and-post DCCV. Propensity score matching revealed no statistically significant difference in outcomes from using NOACs and Warfarin. A cost minimisation study was performed; demonstrating a cost differential of €209 between those administered NOACs and warfarin pre- and post-DCCV. This study demonstrates how using NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-and-post DCCV is cost effective.

Original language	English
Pages (from-to)	P480
Journal	Irish Medical Journal
Volume	109
Issue number	10
Publication status	Published - 1 Nov 2016

Cite this

@article{afd7d630abd944b294642ff525bc3a0c,

title = "A cost minimisation analysis of NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients, pre- and post- cardioversion",

abstract = "Atrial fibrillation can be managed with anticoagulation and restoration of normal sinus rhythm using direct current cardioversion (DCCV). To reduce the risk of thromboembolism, anticoagulation pre-and-post DCCV is recommended. This study investigates the cost effectiveness of using NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-and-post DCCV. Propensity score matching revealed no statistically significant difference in outcomes from using NOACs and Warfarin. A cost minimisation study was performed; demonstrating a cost differential of €209 between those administered NOACs and warfarin pre- and post-DCCV. This study demonstrates how using NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-and-post DCCV is cost effective.",

author = "M. O{\textquoteright}Shea and A. Murphy and Ann Kirby and G. Allen and S. O{\textquoteright}Shea and R. Curtin",

year = "2016",

month = nov,

day = "1",

language = "English",

volume = "109",

pages = "P480",

journal = "Irish Medical Journal",

issn = "0332-3102",

publisher = "Irish Medical Association",

number = "10",

}

TY - JOUR

T1 - A cost minimisation analysis of NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients, pre- and post- cardioversion

AU - O’Shea, M.

AU - Murphy, A.

AU - Kirby, Ann

AU - Allen, G.

AU - O’Shea, S.

AU - Curtin, R.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Atrial fibrillation can be managed with anticoagulation and restoration of normal sinus rhythm using direct current cardioversion (DCCV). To reduce the risk of thromboembolism, anticoagulation pre-and-post DCCV is recommended. This study investigates the cost effectiveness of using NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-and-post DCCV. Propensity score matching revealed no statistically significant difference in outcomes from using NOACs and Warfarin. A cost minimisation study was performed; demonstrating a cost differential of €209 between those administered NOACs and warfarin pre- and post-DCCV. This study demonstrates how using NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-and-post DCCV is cost effective.

AB - Atrial fibrillation can be managed with anticoagulation and restoration of normal sinus rhythm using direct current cardioversion (DCCV). To reduce the risk of thromboembolism, anticoagulation pre-and-post DCCV is recommended. This study investigates the cost effectiveness of using NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-and-post DCCV. Propensity score matching revealed no statistically significant difference in outcomes from using NOACs and Warfarin. A cost minimisation study was performed; demonstrating a cost differential of €209 between those administered NOACs and warfarin pre- and post-DCCV. This study demonstrates how using NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients pre-and-post DCCV is cost effective.

UR - https://www.scopus.com/pages/publications/85009477180

M3 - Article

C2 - 28644585

AN - SCOPUS:85009477180

SN - 0332-3102

VL - 109

SP - P480

JO - Irish Medical Journal

JF - Irish Medical Journal

IS - 10

ER -

A cost minimisation analysis of NOACs compared to warfarin to attain therapeutic anticoagulation amongst AF patients, pre- and post- cardioversion

Abstract

Other files and links

Fingerprint

Cite this